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ABSTRACT 29 
Setting: 10 districts and 3 cities in Zimbabwe 30 
Objective: To compare the yield and relative cost of identifying a case of tuberculosis (TB) 31 
using the three World Health Organization (WHO) recommended algorithms: WHO2b - 32 
symptom inquiry (SI) only; WHO2d - chest X-ray (CXR) after a positive SI; WHO3b - CXR 33 
only; and the Zimbabwe active case finding (ZimACF) algorithm – SI plus CXR to everyone. 34 
Design: Cross-sectional study using data from the ZimACF project. 35 
Results: 38,574 people were screened from April-December 2017 and 488(1.3%) were 36 
diagnosed with TB using the ZimACF algorithm. Using the WHO recommended algorithms, 37 
fewer TB cases would have been diagnosed. This ranged from 7% (34 cases) fewer with 38 
WHO3b, 18% (88 cases) with WHO2b, and 25% (122 cases) with WHO2d. Need for CXR 39 
ranged from 36%(WHO2d) to 100%(WHO3b). Need for bacteriological confirmation ranged 40 
from 7%(WHO2d) to 40%(ZimACF). The relative cost-per-case of TB diagnosed ranged from 41 
$180 with WHO3b to $565 for the ZimACF algorithm. 42 
Conclusion: The ZimACF algorithm had the highest yield but at much greater cost-per-case 43 
than the WHO algorithms. The trade-off between cost and yield needs to be reviewed by the 44 
NTP and a decision to switch to algorithm WHO3b should be considered. 45 
  46 
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INTRODUCTION 47 
Tuberculosis (TB) is the leading cause of deaths among infectious diseases globally. In 2017, 48 
nearly 1.2 million died and 10 million people were affected. 1, 2 Zimbabwe is among the 30 49 
high-burden countries for TB.3 Despite declining TB case notifications in the country, one-50 
third of people with active disease remained undiagnosed in 2017. 1 51 
 52 
Active case finding (ACF) among high-risk groups (HRGs) is effective in identifying 53 
undiagnosed TB.4-6 This leads to earlier initiation on treatment and thus reduce duration of 54 
being infectious and community transmission. 7 Modelling done in high-burden countries 55 
showed that implementing ACF over a 10 year period could reduce TB incidence and mortality 56 
by 27% and 44% respectively. 8 ACF is essential if global targets of the “End TB” Strategy are 57 
to be met. 8, 9  58 
 59 
Zimbabwe’s National TB Programme (NTP) has been implementing ACF since 2017 60 
and it is still ongoing.  The aim is to identify people with undiagnosed TB cases in areas with 61 
estimated high proportions HRGs (see figure 1) and improve treatment coverage. World Health 62 
Organisation (WHO) is not clear on the most appropriate algorithm to use for ACF in resource-63 
limited countries with high HIV and TB prevalence. 10 Countries are encouraged to select an 64 
algorithm that meets their primary objectives for ACF, consider their TB prevalence, HRGs 65 
being targeted, and the resources available.4, 11, 12  66 
 67 
Around 10% of people diagnosed with active TB in some prevalence surveys are 68 
asymptomatic.13-15 It is difficult to identify people with TB disease using symptoms alone in 69 
people living with HIV (PLHIV). It is often paucibacillary hence the need  for clinical 70 
diagnosis.16, 17 Zimbabwe which has a very high TB-HIV co-infection rate of 71%1, so NTP 71 
designed an algorithm 18 which is appreciably different from those recommended by WHO 4 72 
to address these concerns(table 1).  73 
 74 
Literature that compares the yield and cost of WHO-recommended algorithms under 75 
programmatic condition is scarce. We only found one study from China that used data from 76 
elderly people from a  TB prevalence survey.19 However, the burden of both TB and HIV in 77 
their study population was much lower than that in Zimbabwe. 78 
  79 
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The ACF project in Zimbabwe is costly and consumes nearly 20% (over US$1.1 million 80 
dollars) of the total funding for TB in Zimbabwe annually and this was a concern for the NTP. 81 
They requested a review of the screening algorithm to determine if a comparable number of 82 
people with TB could be identified but at a reduced cost. The purpose of our study was to 83 
analyse the characteristics of the population screened in Zimbabwe and use the data to compare 84 
the yield and relative cost of identifying a case of TB if NTP had used one of the three WHO 85 
recommended algorithms.   86 
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METHODS 87 
 88 
Study design 89 
Cross-sectional study using data from the Zimbabwe ACF project. 90 
 91 
Setting  92 
General country profile 93 
Zimbabwe is a developing country in Sub-Saharan African with a population of 17 million in 94 
2017.1 In the same year, 22.5% of the population lived in extreme poverty, defined as 95 
households whose per-capita consumption is less than 2100 calories.20 96 
 97 
The public health system has four levels; central (tertiary), provincial, and district 98 
hospitals, and primary health centres. TB services are free in all public health facilities. Prior 99 
to implementation of ACF, diagnosis of TB was mostly based on passive case finding (PCF).  100 
 101 
Study sites 102 
We used all the available programme data from 10 districts (Beitbridge, Bubi, Chimanimani, 103 
Chiredzi, Masvingo, Matobo, Mutare, Nkayi, Sanyati, and Zvimba) and three city-areas 104 
(Harare, Chitungwiza and Kwekwe) that had been screened in 2017. These places were selected 105 
because they were estimated to have the highest prevalence of undiagnosed TB and targeted 106 
HRGs. Data from these places were also deemed suitable for our study. 107 
 108 
Teams conducting screening used local knowledge to identify places that were most 109 
likely to have high numbers of undiagnosed TB cases in the district or city. Poor overcrowded 110 
communities; places near mines; popular business centres; and areas with limited access to 111 
health services were prioritised. People in these communities were sensitised and mobilised to 112 
come for free TB screening using social media, posters, meetings, print and electronic media. 113 
No incentives were given.   114 
 115 
All people attending the outreach clinics were initially screened for TB symptoms by 116 
nurses. Everyone also had a digital CXR taken and this was interpreted by a doctor on site. 117 
Supervised spot sputum samples were collected from all presumptive TB cases and sent for 118 
bacteriological confirmation at the laboratory. 119 
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 120 
Diagnosis of active TB was through; 121 
a) Bacteriological confirmation – sputum tests positive for TB on GeneXpert or; 122 
b) Clinical diagnosis – the medical doctor makes a decision to diagnose TB based on 123 
the patient’s history, symptoms, signs and CXR findings despite negative sputum 124 
results.  125 
 126 
People were also screened for diabetes and HIV as important co-morbidities. Those 127 
diagnosed were initiated on treatment and linked with their nearest health facility. Tuberculosis 128 
preventive therapy (TPT) was not provided. 129 
 130 
Study population  131 
People screened for TB in Zimbabwe ACF project between April and December 2017. 132 
 133 
Data source and variables  134 
Data from the project stored in the central server was used. During screening, all data were 135 
entered electronically on a tablet. Anonymised data on age, sex, TB symptoms, chest X-ray 136 
(CXR) findings, bacteriological confirmation, HIV status, HRG, and TB diagnosis from the 137 
people screened were extracted. Information on operational costs for staff and the laboratory 138 
for the project was also collected.  139 
 140 
Analysis and statistics 141 
We used STATA version 13.0 (StataCorp LP College Station, Texas, USA) to analyse data. 142 
Encoding errors in seven records were identified using a logic check and excluded. We 143 
calculated the proportion diagnosed with active TB, number needed to be screened (NNS) and 144 
relative cost of identifying one case for individuals with different characteristics and HRGs. 145 
  146 
The data were used to determine for each WHO algorithm, the number and percentage 147 
of people that would be screened for TB symptoms and undergo CXR. We also determined the 148 
number of presumptive TB cases that would have been identified after symptom screening 149 
alone, CXR alone or both sequentially. We then determined from these cases the number who 150 
had active TB diagnosed.  151 
 152 
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A McNemar’s test was used to determine if the number of people diagnosed with TB 153 
by each of the three WHO algorithms was significantly different from the Zimbabwe algorithm 154 
at 5% significance level. The NNS was also calculated for each algorithm. 155 
  156 
We estimated the cost-per-person for conducting symptom screening, having a CXR 157 
taken, and bacteriological confirmation (see table 2). We included only operational staff costs 158 
and laboratory consumables. Other costs related to procurement of capital equipment, 159 
depreciation, maintenance and insurance were assumed to remain constant for all the 160 
algorithms. Direct or indirect patient costs were also not included. 161 
 162 
We calculated the relative cost-per-case diagnosed for each algorithm by dividing the 163 
total cost of the screening by the number of people diagnosed with TB. Sensitivity analysis was 164 
conducted to ascertain if our conclusions on relative cost-per-case for different algorithms 165 
remained the same if we altered the cost assumptions.  166 
 167 
Ethics 168 
Ethical clearance was sought and granted prior to the study by the Medical Research Council 169 
of Zimbabwe (MRCZ/E/198) and The International Union against Tuberculosis and Lung 170 
Disease Ethics Advisory Group (02/18).  171 
 172 
  173 
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RESULTS 174 
A total of 38,574 people were screened for TB in Zimbabwe (Table 3). Almost two-thirds 175 
(61.6%) of them were females. The mean age (standard deviation) of the population was 48 176 
(21) years. Active TB was diagnosed in 488(1.3%) persons, of whom 370(75.8%) were 177 
clinically diagnosed and 118(24.2%) were bacteriologically confirmed.  178 
 179 
The HGRs were not mutually exclusive. Over half (54.9%) of the people screened 180 
belonged to more than one HRG while 41.0% of people screened did not belong to any of the 181 
targeted groups. In total, 1.8% of people with more than one HRG had TB and this was 182 
significantly higher (p < 0.001) than the 0.6% among people who did not belong to any HRG.  183 
   184 
The most common HRGs among the people screened were being a TB contact and 185 
being HIV positive. TB was more common among people previously treated for TB, those who 186 
were HIV positive, and miners.  187 
  188 
In all the algorithms, symptom screening was the initial step for all people except for 189 
WHO3b where the CXR was used first (see Table 4). WHO2d algorithm at 13,710 (35.5%) 190 
would have had the lowest number of people needing to have a CXR done and interpreted by 191 
a medical doctor. With WHO2b algorithm, no CXR would be done.   192 
 193 
The Zimbabwe algorithm had the highest number of presumptive TB cases that needed 194 
bacteriological confirmation, 39.6% (table 4). All the three WHO algorithms would have fewer 195 
numbers of presumptive TB cases identified compared to the Zimbabwe algorithm with 196 
WHO2d at 6.7% being the lowest.  197 
 198 
Table 5 shows that, compared to the number of TB cases diagnosed by the Zimbabwean 199 
algorithm, all the three WHO-recommended screening algorithms would have had a 200 
statistically significant lower yield of TB cases identified (p <0.001). WHO3b, WHO2b and 201 
WHO2d had 7.0%, 18% and 25% fewer cases, respectively.  202 
 203 
The lowest relative cost-per-case was with WHO3b algorithm ($180). It would have 204 
been over three times cheaper than the Zimbabwe algorithm ($565). Sensitivity analysis 205 
showed that despite varying the unit costs used in our model, WHO3b algorithm had a 206 
consistently lower cost-per-case of TB diagnosed compared to the Zimbabwe algorithm.  207 
208 
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DISCUSSION  209 
This is the first study to use data from an ACF program to compare the yield and relative cost 210 
of the WHO-recommended ACF screening algorithms in a high TB and HIV prevalence 211 
setting.  212 
 213 
We found that the current Zimbabwe ACF algorithm gave the highest yield of TB cases 214 
diagnosed. The cost-per-case was triple that of TB diagnosed by the WHO3b algorithm. 215 
However, 7% of active TB cases would be missed by WHO3b algorithm. It is probable that 216 
cases missed would be diagnosed later by PCF in public health facilities. A median delay of 217 
about four weeks is expected with PCF compared to only one week when ACF is done. 21 ACF 218 
should complement rather than replace PCF in finding people with TB disease.5, 11, 12, 22   219 
 220 
 The number of people needing symptom screening, CXR and bacteriological 221 
confirmation was different for the algorithms and this impacts on the relative cost-per-case 222 
(table 4). Participants who did not belong to any HRG had a lower yield of TB and thus 223 
increased the cost per case diagnosed. If the NTP were to adopt the WHO3b algorithm plus 224 
improve the proportion of people with HRG who get screened, significant savings on staff and 225 
laboratory costs could be made.  226 
 227 
The relative cost-per-case of TB diagnosed in this study are markedly different from  a 228 
study carried out in China.19 A similar method was used but data from only elderly people who 229 
participated in a TB prevalence survey were analysed.  In contrast to our study, they reported 230 
that WHO3b algorithm had the best yield but was the most expensive. This is because direct 231 
smear microscopy was used for bacteriological confirmation which is markedly cheaper and 232 
less sensitive than GeneXpert. 23 Unlike in our study where operational staff costs were used 233 
to come up with the cost of a CXR, the China study used market costs which are more 234 
expensive. In addition, the NNS in the China study was more than double that from our study 235 
population reflecting a lower TB prevalence setting. Despite the expense, the Chinese study 236 
also recommended WHO3b algorithm to be used.  237 
 238 
 239 
The strengths of our study were that it used all the available data from people screened 240 
in the Zimbabwean ACF project in normal programmatic conditions.  Data was collected 241 
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electronically during screening. Each patient’s file was verified by the team leader before the 242 
patient was discharged to minimise transcription errors. Our study also adhered to the 243 
Strengthening the Reporting of Observational studies in Epidemiology (STROBE) 244 
guidelines.24 245 
 246 
Limitations of this study were that the costings model we used only generated indicative 247 
costs for the different algorithms. This means the costs cannot be used for international 248 
comparisons or designing a new program.  Also, the results are from areas in Zimbabwe with 249 
the highest estimated prevalence of TB.  Care therefore needs to be taken when generalising 250 
the results to areas with lower TB prevalence. Implementing ACF in such settings may not be 251 
cost-effective.25 The study population was purposively sampled high-risk communities, and 252 
selection bias is also obvious in the male/female ratio. 253 
 254 
The high number of females may reflect differences in health seeking behaviour 255 
between men and women. If more men had participated, a higher yield would have been 256 
expected and hence a lower the cost-per-case across all the algorithms we compared. There 257 
was no significant differences in the number of TB cases diagnosed by gender across all the 258 
algorithms. 259 
 260 
A trade-off could be considered by the NTP when selecting the most appropriate ACF 261 
algorithm. Savings could be used to support other components of the program, particularly TPT 262 
which is recommended for PLHIV when active TB has been excluded.18, 26 Unfortunately, TPT 263 
was not given and that was a missed opportunity. TPT among PLHIV has been shown to reduce 264 
the overall risk of developing TB by around 35%. 8, 27 By integrating TPT within the ACF 265 
program, Zimbabwe could get additional benefits of reducing TB incidence among PLHIV.  266 
 267 
Conclusion  268 
Our study demonstrated that the Zimbabwe ACF algorithm provides the highest yield of TB 269 
cases diagnosed. The WHO3b algorithm will miss seven percent of TB cases but is three times 270 
cheaper.  The NTP should thus consider compromising between cost and yield and adopt the 271 
WHO3b algorithm.    272 
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TABLES AND FIGURES 374 
  375 
High-risk groups for TB in Zimbabwe: 
− People living with HIV infection 
− Contacts of TB patients 
− Miners  
− Healthcare workers (HCWs) 
− People with diabetes mellitus 
− Prisoners  
− The elderly (≥65 years) 
 
Figure 1: High risk groups for TB in 
Zimbabwe 
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Table 1: Comparison of the screening algorithm used in Zimbabwe in 2017 for tuberculosis 376 
with three recommended by WHO,  377 
Algorithm Step 1 Step 2 Step 3 Step 4 
Zimbabwe a Symptom 
enquiry 
If negative or 
positive, go to 
step 2 
 
CXR 
If either one of steps 1 
or 2 are positive, go to 
step 3 
b Bacteriological 
confirmation 
If positive = TB 
diagnosed 
If negative go to step 4 
Clinical review  
Medical doctor reviews 
patient and can make a 
clinical diagnosis of TB 
WHO 2b a Symptom 
enquiry 
If positive, go to 
step 2 
 
b Bacteriological 
confirmation 
If positive = TB 
diagnosed 
If negative go to step 3 
Clinical review  
Medical doctor reviews 
patient and can make a 
clinical diagnosis of TB 
 
WHO 2d a Symptom 
enquiry 
If positive, go to 
step 2 
 
CXR 
If positive, go to step 3 
b Bacteriological 
confirmation 
If positive = TB 
diagnosed 
If negative go to step 4 
Clinical review  
Medical doctor reviews 
patient and can make a 
clinical diagnosis of TB 
WHO 3b 
 
 
 
CXR 
If positive, go to 
step 2 
b Bacteriological 
confirmation 
If positive = TB 
diagnosed 
If negative go to step 3 
Clinical review  
Medical doctor reviews 
patient and can make a 
clinical diagnosis of TB 
 
a Symptom enquiry was for cough of any duration, weight loss, fever, night sweats. The symptom enquiry in 
Zimbabwe did not include haemoptysis as recommended by WHO 
b The GeneXpert was used as the diagnostic test of choice for bacteriological confirmation. 
CXR – chest X-ray; TB – Tuberculosis; WHO – World Health Organisation  
 378 
  379 
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Table 2: Indicative cost* per patient screened in Zimbabwe, 2017 380 
Description Indicative cost per patient screened (USD) 
Symptom screening $1.85 
Chest X-ray $0.93 
Bacteriological confirmation a $11.05 
* using only operational staff costs and laboratory consumables, not capital or maintenance costs 
a GeneXpert was used for bacteriological confirmation  
 381 
  382 
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Table 3: Characteristics of the population screened and cases diagnosed with active 383 
tuberculosis in Zimbabwe, 2017. 384 
Variable Number screened 
for TB 
N (%)a 
Number 
diagnosed with 
TB 
N (%)b 
Number 
needed to 
screen  
N 
Relative cost 
per case 
(USD) 
All clients 38,574  (100) 488  (1.3) 79 $565 
Gender 
Female 
Male  
 
23,761  
14,813  
 
(61.6) 
(38.4) 
 
202  
286  
 
(0.9) 
(2.0) 
 
118 
52 
 
$820 
$385 
Age group 
0 – 4 years 
5 – 14 years 
15 – 24 years 
25 – 34 years 
35 – 44 years 
45 – 54 years 
55 – 64 years 
≥ 65 years 
 
271  
1,471  
2,755  
6,109  
7,735  
6,510  
5,120  
8,603  
 
(0.7) 
(3.8) 
(7.1) 
(15.8) 
(20.1) 
(16.9) 
(13.3) 
(22.3) 
 
2  
12  
18 
50  
103 
99  
78  
126  
 
(0.7) 
(0.8) 
(0.7) 
(0.8) 
(1.4) 
(1.5) 
(1.5) 
(1.5) 
 
136 
123 
153 
122 
75 
66 
66 
68 
 
$1,045 
$906 
$973 
$809 
$524 
$473 
$482 
$527 
Number of HRGs  
People with no HRG 
People with only one HRG 
People with > 1 HRG 
 
15,819 
1,597 
21,158 
 
(41.0) 
(4.1) 
(54.9) 
 
92 
7 
389 
 
(0.6) 
(0.4) 
(1.8) 
 
172 
228 
54 
 
$1,108 
$1,410 
$422 
Type of HRG 
Previously treated for TB 
HIV Status 
Positive c 
Negative 
Unknown 
Miner 
Prisoner 
TB contacts 
Health care workers 
Diabetic d 
 
2,462 
 
6,562 
29,471 
2,541  
3,439 
2,076 
7,250 
1,652 
911 
 
(6.4) 
 
(17.0) 
(76.4) 
(6.6) 
(8.9) 
(5.4) 
(18.8) 
(4.3) 
(2.4) 
 
80 
 
174 
296 
18 
69 
37 
129 
11 
3  
 
(3.3) 
 
(2.7) 
(1.0) 
(0.7) 
(2.0) 
(1.8) 
(1.8) 
(0.7) 
(0.3) 
 
31 
 
38 
100 
141 
50 
56 
56 
150 
304 
 
$276 
 
$296 
$700 
$952 
$397 
$451 
$441 
$925 
$2,151 
a Numbers in the brackets are column percentages;   b Numbers in the brackets are row percentages 
c HIV positive status was based on self-reported HIV positive status or confirmed status after testing 
d Diabetics status was self-reported or a tested random blood glucose of more than 11.1mmol/L  
 TB -  tuberculosis, HIV - human immunodeficiency virus, HRG – High risk group, USD- United States 
dollars 
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Table 4: A comparison of the number of each test that would be required for the four 386 
screening algorithms based on data from Zimbabwe ACF project, 2017. 387 
Algorithm Total 
number 
screened 
Number who had 
symptom screening 
N (%)a 
Number of chest 
X-rays 
N (%)a 
Number of GeneXpert 
tests  
N (%)a 
Zimbabwe 38,574 38,574 (100.0) 38,574 (100.0) 15,260 (39.6) 
WHO 2b 38,574 38,574 (100.0) 0 (0.0) 13,710 (35.5) 
WHO 2d 38,574 38,574 (100.0) 13,710 (35.5) 2,595 (6.7) 
WHO 3b 38,574 0 (0.0) 38,574 (100.0) 4,145 (10.8) 
a Numbers in brackets represent row percentages 
Zimbabwean – Zimbabwean algorithm: everyone is screened using both symptoms and chest X-ray and if 
either are positive, they go for bacteriological confirmation 
WHO 2b – WHO algorithm: people are initially screened using symptoms and if positive they go for 
bacteriological confirmation 
WHO 2d – WHO algorithm: people are initially screened for symptoms and if positive they go for a chest X-
ray and if positive for bacteriological confirmation  
WHO 3b – WHO algorithm: people are initially screened by   chest X-ray and if positive go for 
bacteriological confirmation 
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Table 5: A comparison of the number of TB cases diagnosed, number needed to screen, and relative 390 
cost per case diagnosed using four different screening algorithms based on data from Zimbabwe, 2017. 391 
Algorithm 
Number 
screened 
N 
Number diagnosed with active TB Number 
needed 
to screen 
N 
Relative 
cost per 
case 
(USD) 
All cases  
N (%) 
Clinically 
diagnosed 
N (%) 
Bacteriologically 
confirmed 
N (%) 
Zimbabwe 38,547 488 (1.3) 370 (75.8) 118 (24.2) 79 $565 
WHO 2b 38,547 400a (1.0) 294 (73.5) 106 (26.5) 96 $557 
WHO 2d 38,547 366a (0.9) 282 (77.0) 84 (23.0) 105 $308 
WHO 3b 38,547 454a (1.2) 358 (78.9) 96 (21.1) 85 $180 
a McNemar’s test showed the number of active TB cases diagnosed was significantly different (p-value <0.001) 
compared to the Zimbabwean algorithm 
Zimbabwean – Zimbabwean algorithm: everyone is screened using both symptoms and chest X-ray and if 
either are positive, they go for bacteriological confirmation 
WHO 2b – WHO algorithm: people are initially screened using symptoms and if positive they go for 
bacteriological confirmation 
WHO 2d – WHO algorithm: people are initially screened for symptoms and if positive they go for a chest X-ray 
and if positive for bacteriological confirmation  
WHO 3b – WHO algorithm: people are initially screened by chest X-ray and if positive go for bacteriological 
confirmation 
USD – United States dollars 
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